Press release
PHAXIAM Receives Compliance Notice from Nasdaq
![](https://phaxiam.com/wp-content/uploads/2023/09/newsroom_bandeau-960x406-1.jpeg)
PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM today announced that it has received confirmation
from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2).